Log in

Relevant bibliographies by topics / P-Glycoprotein inhibition

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers

Academic literature on the topic 'P-Glycoprotein inhibition'

Author: Grafiati

Published: 4 June 2021

Last updated: 2 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'P-Glycoprotein inhibition.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "P-Glycoprotein inhibition"

1

Leveille-Webster, C. "The perils of P-glycoprotein inhibition." Hepatology 24, no. 1 (1996): 276–79. http://dx.doi.org/10.1002/hep.510240146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Fujise, Hiroshi, Shigemi Sasawatari, Takeshi Annoura, Teruo Ikeda, and Kazumitsu Ueda. "3,3′,4,4′,5-Pentachlorobiphenyl Inhibits Drug Efflux Through P-Glycoprotein in KB-3 Cells Expressing Mutant Human P-Glycoprotein." Journal of Biomedicine and Biotechnology 2004, no. 3 (2004): 137–42. http://dx.doi.org/10.1155/s1110724304308028.

Full text

Abstract:

The effects on the drug efflux of3,3′,4,4′,5-pentachlorobiphenyl (PCB-126), the most toxic of all coplanar polychlorinated biphenyls (Co-PCBs), were examined in KB-3 cells expressing human wild-type and mutant P-glycoprotein in which the 61st amino acid was substituted for serine or phenylalanine (KB3-Phe61). In the cells expressing P-glycoproteins, accumulations of vinblastine and colchicine decreased form 85% to 92% and from 62% to 91%, respectively, and the drug tolerances for these chemicals were increased. InKB3-Phe61, the decreases in drug accumulation were inhibited by adding PCB-126 in

APA, Harvard, Vancouver, ISO, and other styles

3

Amin, Md Lutful. "P-glycoprotein Inhibition for Optimal Drug Delivery." Drug Target Insights 7 (January 2013): DTI.S12519. http://dx.doi.org/10.4137/dti.s12519.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

LeBlanc, Gerald A. "Inhibition of P-glycoprotein in tumour cells." Emerging Therapeutic Targets 2, no. 1 (1998): 121–23. http://dx.doi.org/10.1517/14728222.2.1.121.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Weiss, Johanna, Sven-Maria Gregor Dormann, Meret Martin-Facklam, Christian Johannes Kerpen, Nahal Ketabi-Kiyanvash, and Walter Emil Haefeli. "Inhibition of P-Glycoprotein by Newer Antidepressants." Journal of Pharmacology and Experimental Therapeutics 305, no. 1 (2003): 197–204. http://dx.doi.org/10.1124/jpet.102.046532.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Fromm, Martin F., Richard B. Kim, C. Michael Stein, Grant R. Wilkinson, and Dan M. Roden. "Inhibition of P-Glycoprotein–Mediated Drug Transport." Circulation 99, no. 4 (1999): 552–57. http://dx.doi.org/10.1161/01.cir.99.4.552.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kapoor, Karan, Shashank Pant, and Emad Tajkhorshid. "Lipid-Mediated Inhibition Mechanism of P-Glycoprotein." Biophysical Journal 116, no. 3 (2019): 126a. http://dx.doi.org/10.1016/j.bpj.2018.11.702.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Fenyvesi, Ferenc, Éva Fenyvesi, Lajos Szente, et al. "P-glycoprotein inhibition by membrane cholesterol modulation." European Journal of Pharmaceutical Sciences 34, no. 4-5 (2008): 236–42. http://dx.doi.org/10.1016/j.ejps.2008.04.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kurnik, Daniel, Gbenga G. Sofowora, John P. Donahue, et al. "Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein." Anesthesiology 109, no. 6 (2008): 1092–99. http://dx.doi.org/10.1097/aln.0b013e31818d8f28.

Full text

Abstract:

Background Loperamide, a potent opioid, has been used as an in vivo probe to assess P-glycoprotein activity at the blood-brain barrier, because P-glycoprotein inhibition allows loperamide to cross the blood-brain barrier and exert its central opioid effects. In humans, studies with nonselective and moderately potent inhibitors resulted in mild opioid effects but were confounded by the concurrent inhibition of loperamide's metabolism. The authors studied the effect of the highly selective, potent P-glycoprotein inhibitor tariquidar on loperamide's central opioid effects. Methods In a randomized

APA, Harvard, Vancouver, ISO, and other styles

10

Eberl, Sonja, Bertold Renner, Antje Neubert, et al. "Role of P-Glycoprotein Inhibition for Drug Interactions." Clinical Pharmacokinetics 46, no. 12 (2007): 1039–49. http://dx.doi.org/10.2165/00003088-200746120-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "P-Glycoprotein inhibition"

1

Zeino, Maen [Verfasser]. "Cytotoxicity and P-glycoprotein inhibition by cardiotonic steroids / Maen Zeino." Mainz : Universitätsbibliothek der Johannes Gutenberg-Universität Mainz, 2015. http://d-nb.info/1225685648/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Palmeira, Andreia Filipa dos Santos. "Design Synthesis and Evaluation of Xanthone Derivatives for Dual Activity: Antitumor and P-Glycoprotein Inhibition." Tese, Faculdade de Farmácia da Universidade do Porto, 2010. http://hdl.handle.net/10216/63796.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Palmeira, Andreia Filipa dos Santos. "Design Synthesis and Evaluation of Xanthone Derivatives for Dual Activity: Antitumor and P-Glycoprotein Inhibition." Doctoral thesis, Faculdade de Farmácia da Universidade do Porto, 2010. http://hdl.handle.net/10216/63796.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Hevér, Aniko. "Inhibition of P-glycoprotein mediated efflux and modulation of MDR-1 gene expression in tumor cells by newly synthesised azaheteroyclic derivatives." Aix-Marseille 2, 1998. http://theses.univ-amu.fr.lama.univ-amu.fr/PHA_1998_1512.pdf.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Wan, Chung Ping Leon. "The effect of P-glycoprotein inhibition and ultrasound exposure on the cytotoxicity of taxane loaded diblock copolymer nanoparticles in multidrug resistant cells." Thesis, University of British Columbia, 2014. http://hdl.handle.net/2429/49957.

Full text

Abstract:

One of the major mechanisms of multidrug resistance involves an efflux protein, P-glycoprotein (Pgp), which pumps commonly used anticancer drugs such as taxanes out of cells, leading to a decrease in cellular drug accumulation. The overall goal of this project was to develop strategies to enhance intracellular drug accumulation and cytotoxicity of nanoparticulate taxanes in multi-drug resistant (MDR) cell lines. Paclitaxel (PTX) loaded nanoparticles fabricated from micelle forming MePEG₁₁₄-b-PCL₁₉ and nanosphere forming MePEG₁₁₄-b-PCL₁₀₄ were compared for drug and block copolymer uptake, and c

APA, Harvard, Vancouver, ISO, and other styles

6

Djuv, Ane. "Co-Use of Drugs and Herbal Remedies in General Practice and In Vitro Inhibition of CYP3A4, CYP2D6 and P-Glycoprotein by the Common Herb Aloe Vera." Doctoral thesis, Norges teknisk-naturvitenskapelige universitet, Institutt for kreftforskning og molekylær medisin, 2013. http://urn.kb.se/resolve?urn=urn:nbn:no:ntnu:diva-23578.

Full text

Abstract:

There is a widespread use of complementary and alternative medicine (CAM) and herbal remedies in particular in different patients groups, but very few are published about co-use among patients in general practice (GP) and herb-drug combinations at risk. Co-use of herbal remedies and drugs can result in none or server adverse effects. Of this reason, knowledge about the GP patients co-use and research on mechanisms of such interactions is needed. The aims of this thesis were divided; 1) To register the co-use of drugs and herbs among GP patients in Norway and the patients communication of such

APA, Harvard, Vancouver, ISO, and other styles

7

Sonawane, Amit. "Evaluation of novel efflux transport inhibitor for the improvement of drug delivery through epithelial cell monolayer." Thesis, University of Bradford, 2015. http://hdl.handle.net/10454/14424.

Full text

Abstract:

Blood-brain barrier (BBB) is a unique membranous barrier, which segregates brain from the circulating blood. It works as a physical and metabolic barrier between the central nervous system (CNS) and periphery. In mammals, endothelial cells were shown to be of BBB and are characterized by the tight junctions along with efflux system which are responsible for the restriction of movement of molecules within the cells. Efflux system consists of multidrug resistance proteins such as P-glycoprotein (P-gp). P-gp removes substances out back from the brain to the blood before they reach to the brain. S

APA, Harvard, Vancouver, ISO, and other styles

8

Araújo, Ana Patrícia Loureiro Machado Gomes de. "O papel da glicoproteína-P nas interações fármaco-fármaco." Master's thesis, [s.n.], 2015. http://hdl.handle.net/10284/5156.

Full text

Abstract:

Projeto de Pós-Graduação/Dissertação apresentado à Universidade Fernando Pessoa como parte dos requisitos para obtenção do grau de Mestre em Ciências Farmacêuticas<br>A glicoproteína-p (gp-P) foi descrita pela primeira vez em 1976 como uma glicoproteína de superfície presente na membrana citoplasmática. Esta é uma bomba de efluxo que pertence à família de transportadores ABC e que participa no fenómeno de resistência a múltiplos fármacos. Encontra-se amplamente distribuída nos tecidos e participa em variadas funções fisiológicas importantes. É expressa nos pontos de entrada dos xenobiótic

APA, Harvard, Vancouver, ISO, and other styles

9

Jain, Ritesh Mitra Ashim K. "A novel approach to circumvent P-glycoporotein mediated cellular efflux and permeability enhancement of HIV protease inhibitor saquinavir." Diss., UMK access, 2007.

Find full text

Abstract:

Thesis (Ph. D.)--School of Pharmacy. University of Missouri--Kansas City, 2007.<br>"A dissertation in pharmaceutical science and pharmacology." Advisor: Ashim K. Mitra. Typescript. Vita. Title from "catalog record" of the print edition Description based on contents viewed July 16, 2008. Includes bibliographical references (leaves 231-248). Online version of the print edition.

APA, Harvard, Vancouver, ISO, and other styles

10

Jeanjean, Bruno. "Inhibition exercee par la substance p sur la secretion antehypophysaire de lh, induite par le gnrh, chez la ratte : role de l'estradiol-17beta et de la progesterone sur la secretion hypothalamique de la substance p, chez la guenon." Paris 6, 1988. http://www.theses.fr/1988PA066310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "P-Glycoprotein inhibition"

1

Huq, Rokaiya. Energy metabolism in human MCF-7 ADR and ADR-9 breast cancer cells treated with P-glycoprotein inhibitor PSC 833. Laurentian University, 2000.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kankesan, Janarthanan. Studies on the effect of PSC 833, a potent inhibitor of P-glycoprotein function on the development of cancer /cby Janarthanan Kankesan. 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "P-Glycoprotein inhibition"

1

Jeremić, Svetlana, and Zoran Marković. "Free Radical Scavenger Activity and P-glycoprotein Inhibition Capacity of 1,2,4-Trihydroxyxanthone." In Learning and Analytics in Intelligent Systems. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-43658-2_9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Hamada, Hirofumi, and Takashi Tsuruo. "Growth Inhibition of Multidrug-Resistant Cells by Monoclonal Antibodies against P-Glycoprotein." In Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells. Springer US, 1991. http://dx.doi.org/10.1007/978-1-4615-3794-6_20.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Newman, Michael J., Ross Dixon, and Barry Toyonaga. "OC144-093, a Novel P glycoprotein Inhibitor for the Enhancement of Anti-Epileptic Therapy." In Novartis Foundation Symposia. John Wiley & Sons, Ltd, 2008. http://dx.doi.org/10.1002/0470846356.ch16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

M. Jasim, Adnan, and Mohammed J. Jawad. "Pharmaceutical Applications of Vitamin E TPGS." In Vitamin E in Health and Disease - Interactions, Diseases and Health Aspects [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.97474.

Full text

Abstract:

D-tocopheryl polyethylene glycol succinate (Vitamin E TPGS) has been approved as a safe pharmaceutical adjuvant by FDA, and several drug delivery systems (DDS) based on TPGS have been developed. TPGS properties as a P-gp inhibitor, solubilizer/absorption and permeation enhancer in drug delivery and TPGS-related formulations such as nanocrystals, nanosuspensions, tablets/solid dispersions, vaccine system adjuvant, nutritional supplement, film plasticizer, anticancer reagent, and so on, are discussed in this review. Consequenly, TPGS can inhibit ATP-dependent P-glycoprotein activity and act as a potent excipient that promotes the efficiency of delivery and the therapeutic effect of drugs. Inhibition of P-gp occurs through mitochondria-dependent inhibition of the P-gp pump. Many of the latest studies address the use of TPGS for many poorly water-soluble or permeable drugs in the manufacture of nanodrugs or other formulations. In addition, it has been reported that TPGS shows a robust improvement in chylomicron secretion at low concentrations and improves intestinal lymphatic transport, which would also boost the potential of drug absorption. It also indicates that there are still many problems facing clinical translation of TPGS-based nanomedicines, requiring a more deep evaluation of TPGS properties and a future-based delivery method.

APA, Harvard, Vancouver, ISO, and other styles

5

Turner, Adrian P., Camille Alam, and Reina Bendayan. "Efflux transporters in cancer resistance: Molecular and functional characterization of P-glycoprotein." In Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-816434-1.00001-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

L. Stockert, Amy, and Seth Hall. "Therapeutic Potential of Dietary Polyphenols." In Functional Foods [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99177.

Full text

Abstract:

The chapter summarizes available research on polyphenols and the potential for polyphenol based therapeutics. Polyphenols have the potential to be used in a multi-target fashion therapeutically. The majority of the polyphenol benefits appear to share positive effects across multiple disease states including inflammatory diseases, diseases of metabolic dysregulation and cancer. The reviewed literature includes human, animal and cell culture based studies. Selected mechanisms within each disease state are highlighted including interleukin inflammatory markers, NF-κB, acetyl-CoA concentration regulation of metabolism, and p-glycoprotein multidrug efflux pump associated with cancer treatment failures. Reviewed studies discuss polyphenols inhibiting transcription factors that control expression on inflammatory factors as well as activating other transcription factors that increase expression of enzymes protective of oxidative damage. Levels of metabolic regulatory enzymes are also affected positively by polyphenol addition through epigenetic modifications. Epigenetic modifications affecting cancer development and progression appear positively affected by polyphenol treatment. Additionally, oxidative damage protection of normal cells can be achieved by polyphenol treatment thus limiting chemotherapeutic damage. Upon review of the available literature, a strong case for the potential use of polyphenols in therapeutic situations stands out. Potential risks included are that the purity and specific concentrations required to achieve therapeutic benefits without potential side effects need to be examined prior to the adoption of therapeutics.

APA, Harvard, Vancouver, ISO, and other styles

7

Cozza, Kelly L., and Harold W. Goforth. "Psychopharmacologic Treatment Issues in AIDS Psychiatry." In Handbook of AIDS Psychiatry. Oxford University Press, 2010. http://dx.doi.org/10.1093/oso/9780195372571.003.0011.

Full text

Abstract:

Persons with HIV and AIDS are often prescribed a plethora of medications, all of which require special attention and are based on well-defined principles. In the first part of this chapter, Drug Interaction Principles, we provide a short but essential review of these principles in order to prepare the reader to critically weigh the potential for drug interactions between psychotropics and antiretroviral therapy (ART) and those between ART and other medications. In the second part, Psychotropics and HIV, a brief review of the available literature on the effectiveness of psychotropics in treating patients with HIV is provided, followed by an overview of issues relating to drug interactions for each psychotropic or class of psychotropic. The third part of the chapter, Antiretrovirals, provides an introductory overview of currently available antiretrovirals and of medications prescribed in treating HIV/AIDS. Readers are referred to an excellent review of pharmacological treatment for persons with addictions and HIV/AIDS, by Wynn and colleagues (2005), and to Chapters 2, 6, 8, and 10 of this handbook for more information on treating substance abuse and dependence. Understanding drug–drug interactions in the care of HIV patients is essential. For a full explanation of psychotropic pharmacology and drug interactions, the reader is referred to additional texts on the subject (Cohen and Gorman, 2008; Schatzberg and Nemeroff, 2009; Wynn et al., 2009). Pharmacodynamic interactions are those that occur at the intended receptor site of a medication and involve absorption, distribution, metabolism, and excretion. ART drugs may be affected by timing with food or buffers, which is relatively predictable. Metabolic interactions are a bit more complex, as they are affected by metabolic inhibition, induction, and pharmacogenetics (the particular metabolic enzymes that a patient is born with). Metabolic interactions may occur in either phase I or II metabolic enzymes and also may include the cell membrane transporter enzymes (also known as p-glycoproteins). For a complete explanation of pharmacokinetic interactions, the reader is referred to the text by Wynn et al. (2009).

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "P-Glycoprotein inhibition"

1

Farrell, Christopher L., Rebecca Mahan, Catherine Blauvelt, Taylor Kaye Servais, and Jessica Lane. "Abstract 1974: Inhibition of the P-glycoprotein with a novel agent in overexpressing P-glycoprotein chemotherapy resistant colorectal cancer cells." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1974.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Datta, Amrita, Barbara J. Rider, Zakaria Y. Abd Elmageed, Hogyoung Kim, Debasis Mondal, and Asim B. Abdel Mageed. "Abstract 1701: A synthetic flavonoid abrogates doxorubicin resistance through inhibition of focal adhesion kinase and P-glycoprotein activity in breast cancer cells." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1701.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Singh, Ashok, Anupama Singh, Satyamedha Bathula, Saivenkateshkomal Bathula, and Ajit K. Verma. "Abstract 2142: Plumbagin, a medicinal plant-derived naphthoquinone, inhibits the growth of docetaxel resistant prostate cancer cells via inhibition of the expression of P-glycoprotein and NF-kB activation." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-2142.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Gewirtz, A., W. Y. Xu, B. Rucinski, and S. Niewiarowski. "SELECTIVE INHIBITION OF HUMAN MEGAKARYOCYTOPOIESIS IN VITRO BY HIGHLY PURIFIED PLATELET FACTOR 4." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644621.

Full text

Abstract:

Platelet (plt) factor 4 (PF4) is an alpha granule protein which can modulate T lymphocyte function. T cells may help regulate megakaryocytopoiesis. Therefore, we hypothesized that T cell-PF4 interactions might play a role in autoregulating marrow megakaryocyte (MEG) production. To test this idea, we studied MEG colony formation in plasma clot cultures containing human serum derived solely from pit poor normal AB plasma, enriched hematopoietic progenitor cells (HPC), autologous T cells, and exogenous PF4. Highly purified PF4 (single band on SDS gel) was prepared from outdated human pits by a co

APA, Harvard, Vancouver, ISO, and other styles

5

Yang, Shun-Fa, Ming-Ju Hsieh, and Chiao-Wen Lin. "Abstract 4261: Upregulation of miR-34b, miR-892a and inhibition of p-glycoprotein play an important role for melatonin-induced apoptosis and autophagy in vincristine-resistant human oral cancer cells." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Yang, Shun-Fa, Ming-Ju Hsieh, and Chiao-Wen Lin. "Abstract 4261: Upregulation of miR-34b, miR-892a and inhibition of p-glycoprotein play an important role for melatonin-induced apoptosis and autophagy in vincristine-resistant human oral cancer cells." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Prasad Dash, Ranjeet, Bhanuchander Ellendula, and Manish Nivsarkar. "Influence of diabetes progression on intestinal absorption of P-glycoprotein substrate: Implication of epigallocatechin-3-gallate (P-glycoprotein inhibitor) for reducing intestinal drug efflux." In Annual International Conference on Pharmaceutical Sciences and Pharmacology. Global Science & Technology Forum (GSTF), 2013. http://dx.doi.org/10.5176/2345-783x_pharma13.08.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zhou, Wen-jing, Fang Wang, Xu Zhang, Kenneth Kin Wah To, Hong-bing Huang, and Li-Wu Fu. "Abstract 773: Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-773.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Alqahtani, Salwa D., Hanan A. Assiri, Fahad A. Al-Abbasi, Ali M. El-Halawany, and Ahmed M. Al-Abd. "Abstract 1205: Rubrofusarin and toralactone sensitize resistant MCF-7adrcell line to paclitaxel via inhibiting P-glycoprotein efflux activity." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-1205.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lei, Zi-Ning, Zhongzhi Wu, Qiu-Xu Teng, et al. "Abstract 5264: Selective toxicity of MX-106-4C, a survivin inhibitor, in P-glycoprotein-mediated multidrug resistant colon cancer." In Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-5264.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!